⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12416160 | 1.00 | — | — | |
| SCHEMBL19051013 | 1.00 | — | — | |
| SCHEMBL19760424 | 1.00 | — | — | |
| SCHEMBL19078920 | 0.86 | SSTR1 (0.34) | — | |
| SCHEMBL19760422 | 0.86 | SSTR1 (0.34) | — | |
| SCHEMBL10366417 | 0.85 | FGF1 (0.31) | — | |
| SCHEMBL18294595 | 0.85 | FGF1 (0.33) | — | |
| SCHEMBL19051014 | 0.85 | FGF1 (0.33) | — | |
| SCHEMBL25605193 | 0.85 | FGF1 (0.33) | — | |
| SCHEMBL25594520 | 0.85 | FGF1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209368-A1 | EXTRACELLULAR VESICLE COMPOSITIONS | LONZA SALES AG (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240018519-A1 | Stabilized saRNA Compositions and Methods of Use | MINA THERAPEUTICS LIMITED (GB) | 2024-01-18 | — | — | US | disclosed |
| US-20230399643-A1 | COMPLEMENT COMPONENT C1S INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME | GENENTECH, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230364127-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | CODIAK BIOSCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230331837-A1 | OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230323362-A1 | COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME | GENENTECH, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230323421-A1 | OLIGONUCLEOTIDES TARGETING XBP1 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-10-12 | — | — | US | disclosed |
| US-20230313189-A1 | COMPLEMENT COMPONENT 4 INHIBITORS FOR TREATING NEUROLOGICAL DISEASES, AND RELATED COMPOSITONS, SYSTEMS AND METHODS OF USING SAME | GENENTECH, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230304089-A1 | IN VITRO NEPHROTOXICITY SCREENING ASSAY | HOFFMANN-LA ROCHE INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230302036-A1 | COMPOSITIONS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | UNIVERSIDAD DE BUENOS AIRES (AR) | 2023-09-28 | — | — | US | disclosed |
| US-20230287412-A1 | Oligonucleotide Agonists Targeting Progranulin | HOFFMANN-LA ROCHE INC. | 2023-09-14 | — | — | US | disclosed |
| US-11753640-B2 | Oligonucleotides for modulating Tau expression | HOFFMANN-LA ROCHE INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11732262-B2 | Use of FUBP1 inhibitors for treating hepatitis B virus infection | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2023-08-22 | — | — | US | disclosed |
| US-20230241089-A1 | STING AGONIST COMPRISING EXOSOMES FOR TREATING NEUROIMMUNOLOGICAL DISORDERS | CODIAK BIOSCIENCES, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230210887-A1 | NUCLEIC ACID MOLECULES FOR REDUCTION OF PAPD5 OR PAPD7 MRNA FOR TREATING HEPATITIS B INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212572-A1 | Guanosine Analogues for Use in Therapeutics Polynucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2023-07-06 | — | — | US | disclosed |
| US-20230193269-A1 | OLIGONUCLEOTIDES FOR SPLICE MODULATION OF CARD9 | BOEHRINGER INGELHEIM INT (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230183692-A1 | USE OF SEPT9 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. | 2023-06-15 | — | — | US | disclosed |
| US-20170283496-A1 | OLIGONUCLEOTIDES FOR REDUCTION OF PD-L1 EXPRESSION | HOFFMANN-LA ROCHE INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170191064-A1 | OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-07-06 | — | — | US | disclosed |